Expanded Access to Avelumab for Treatment of Metastatic Merkel Cell Carcinoma (mMCC)

Metastatic Merkel Cell Carcinoma Clinical Trial

Official title:
Temporary Authorization for Use (ATU) to Avelumab for Treatment of Adult Patients With Metastatic Merkel Cell Carcinoma (mMCC)

Status Approved for marketing

Clinical Trial Summary

Expanded access to Avelumab solution for infusion will be made available for adult patients with mMCC whose disease has progressed after receiving at least one prior chemotherapy.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03089658
Study type	Expanded Access
Source	Merck KGaA, Darmstadt, Germany
Contact
Status	Approved for marketing
Phase

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05947500` - Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial	Phase 2
Recruiting	`NCT04261855` - Targeted Therapy and Avelumab in Merkel Cell Carcinoma	Phase 1/Phase 2
Active, not recruiting	`NCT03816332` - Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers	Phase 1
Recruiting	`NCT05269381` - Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors	Phase 1
Active, not recruiting	`NCT03304639` - Testing the Addition of Radiation Therapy to Immunotherapy for Merkel Cell Carcinoma	Phase 2
Active, not recruiting	`NCT03599713` - A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201)	Phase 2
Recruiting	`NCT05896839` - Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer	Phase 1/Phase 2